Bristol-Myers Bristol-Myers Squibb Co (BMY.US) announced that FDA in the United States has granted it the qualification of antibody coupling therapy CC-99712 orphan drug targeting BCMA for the treatment of multiple myeloma.

It is reported that CC-99712 therapy is a product jointly developed by Bristol-Myers Bristol-Myers Squibb Co and Sutro Biopharma (STRO.US), which can couple cytotoxic drugs to specific sites of antibodies, thus controlling the drug antibody ratio (DAR) to 4. The control of DAR is helpful to control the safety and efficacy of the treatment.

Currently, the first phase of the CC-99712 trial has been registered, and Bristol-Myers Bristol-Myers Squibb Co has the right to develop and commercialize the experimental treatment globally.